Weekly Research Analysts’ Ratings Updates for Sutro Biopharma (STRO)

A number of firms have modified their ratings and price targets on shares of Sutro Biopharma (NASDAQ: STRO) recently:

• 3/17/2025 – Sutro Biopharma had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock, down previously from $12.00.
• 3/14/2025 – Sutro Biopharma was given a new $2.00 price target on by analysts at Piper Sandler.
• 3/14/2025 – Sutro Biopharma was downgraded by analysts at Bank of America Co. from a “buy” rating to an “underperform” rating. They now have a $1.00 price target on the stock, down previously from $11.00.
• 3/14/2025 – Sutro Biopharma was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” rating. They now have a $2.00 price target on the stock, down previously from $8.00.
• 3/14/2025 – Sutro Biopharma was downgraded by analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating.
• 3/14/2025 – Sutro Biopharma was downgraded by analysts at Piper Sandler from a “strong-buy” rating to a “hold” rating.

Sutro Biopharma Stock Performance

STRO stock opened at $0.90 on Wednesday. Sutro Biopharma, Inc. has a 52-week low of $0.76 and a 52-week high of $6.13. The business has a 50-day simple moving average of $1.71 and a two-hundred day simple moving average of $2.67. The company has a market capitalization of $73.89 million, a P/E ratio of -0.56 and a beta of 1.22.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Thursday, March 13th. The company reported ($2.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The business had revenue of $14.00 million for the quarter, compared to the consensus estimate of $10.44 million. During the same period in the previous year, the firm earned ($1.78) EPS. As a group, sell-side analysts forecast that Sutro Biopharma, Inc. will post -2.92 earnings per share for the current fiscal year.

Institutional Trading of Sutro Biopharma

Several institutional investors have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC raised its stake in shares of Sutro Biopharma by 3.8% during the fourth quarter. Suvretta Capital Management LLC now owns 7,462,495 shares of the company’s stock valued at $13,731,000 after acquiring an additional 275,000 shares during the last quarter. Vestal Point Capital LP bought a new position in shares of Sutro Biopharma during the fourth quarter valued at about $4,729,000. Geode Capital Management LLC raised its stake in shares of Sutro Biopharma by 7.7% during the third quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock valued at $6,426,000 after acquiring an additional 132,015 shares during the last quarter. Parkman Healthcare Partners LLC raised its stake in shares of Sutro Biopharma by 0.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 1,727,925 shares of the company’s stock valued at $3,179,000 after acquiring an additional 11,793 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Sutro Biopharma by 5.2% during the third quarter. State Street Corp now owns 1,647,162 shares of the company’s stock valued at $5,699,000 after acquiring an additional 81,855 shares during the last quarter. 96.99% of the stock is currently owned by hedge funds and other institutional investors.

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.